{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:41:56Z","timestamp":1740120116495,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T00:00:00Z","timestamp":1499385600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s12185-017-2297-y","type":"journal-article","created":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T09:46:32Z","timestamp":1499420792000},"page":"681-690","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Retrospective analysis of prognostic factors for Waldenstr\u04e7m macroglobulinemia: a multicenter cooperative study in Japan"],"prefix":"10.1007","volume":"106","author":[{"given":"Akio","family":"Saito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3080-2341","authenticated-orcid":false,"given":"Atsushi","family":"Isoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Yokohama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Tsukune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Ohtsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiaki","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayoko","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Moriya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morio","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Nakahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakae","family":"Tanosaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Sakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihide","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Miyanaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Handa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norifumi","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,7]]},"reference":[{"key":"2297_CR1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","volume":"30","author":"RG Owen","year":"2003","unstructured":"Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenstrom\u2019s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia. Semin Oncol. 2003;30:110\u20135.","journal-title":"Semin Oncol"},{"key":"2297_CR2","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.1993.11.8.1553","volume":"11","author":"T Facon","year":"1993","unstructured":"Facon T, Brouillard M, Duhamel A, Morel P, Simon M, Jouet JP, et al. Prognostic factors in Waldenstr\u00f6m\u2019s macroglobulinemia: a report of 167 cases. J Clin Oncol. 1993;11:1553\u20138.","journal-title":"J Clin Oncol"},{"key":"2297_CR3","first-page":"852","volume":"96","author":"P Morel","year":"2000","unstructured":"Morel P, Monconduit M, Jacomy D, Lenain P, Grosbois B, Bateli C, et al. Prognostic factors in Waldenstr\u00f6m\u2019s macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood. 2000;96:852\u20138.","journal-title":"Blood"},{"key":"2297_CR4","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1046\/j.1365-2141.2001.03144.x","volume":"115","author":"R Garcia-Sanz","year":"2001","unstructured":"Garcia-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A, et al. Waldenstr\u00f6m macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol. 2001;115:575\u201382.","journal-title":"Br J Haematol"},{"key":"2297_CR5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1053\/sonc.2003.50064","volume":"30","author":"G Merlini","year":"2003","unstructured":"Merlini G, Baldini L, Broglia C, Comelli M, Goldaniga M, Palladini G, et al. Prognostic factors in symptomatic Waldenstrom\u2019s macroglobulinemia. Semin Oncol. 2003;30:211\u20135.","journal-title":"Semin Oncol"},{"key":"2297_CR6","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood.V83.10.2939.2939","volume":"83","author":"PG Gobbi","year":"1994","unstructured":"Gobbi PG, Bettini R, Montecucco C, Cavanna L, Morandi S, Pieresca C, et al. Study of prognosis in Waldenstr\u00f6m\u2019s macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood. 1994;83:2939\u201345.","journal-title":"Blood"},{"key":"2297_CR7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2006.06003.x","volume":"133","author":"IM Ghobrial","year":"2006","unstructured":"Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, Larson DR, Therneau TM, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2006;133:158\u201364.","journal-title":"Br J Haematol"},{"key":"2297_CR8","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1309\/4LCN-JMPG-5U71-UWQB","volume":"116","author":"RG Owen","year":"2001","unstructured":"Owen RG, Barrans SL, Richards SJ, O\u2019Connor SJ, Child JA, Parapia LA, et al. Waldenstr\u00f6m macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol. 2001;116:420\u20138.","journal-title":"Am J Clin Pathol"},{"key":"2297_CR9","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/annonc\/mdg334","volume":"14","author":"MA Dimopoulos","year":"2003","unstructured":"Dimopoulos MA, Hamilos G, Zervas K, Symeonidis A, Kouvatseas G, Roussou P, et al. Survival and prognostic factors after initiation of treatment in Waldenstrom\u2019s macroglobulinemia. Ann Oncol. 2003;14:1299\u2013305.","journal-title":"Ann Oncol"},{"key":"2297_CR10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood.V98.1.41","volume":"98","author":"MV Dhodapkar","year":"2001","unstructured":"Dhodapkar MV, Jacobson JL, Gertz MA, Rivkin SE, Roodman GD, Tuscano JM, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenstr\u00f6m macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood. 2001;98:41\u20138.","journal-title":"Blood"},{"key":"2297_CR11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3816\/CLM.2006.n.060","volume":"7","author":"A Anagnostopoulos","year":"2006","unstructured":"Anagnostopoulos A, Zervas K, Kyrtsonis M, Symeonidis A, Gika D, Bourantas K, et al. Prognostic value of serum beta2-microglobulin in patients with Waldenstrom\u2019s macroglobulinemia requiring treatment. Clin Lymphoma Myeloma. 2006;7:205\u20139.","journal-title":"Clin Lymphoma Myeloma."},{"key":"2297_CR12","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.leukres.2010.04.005","volume":"34","author":"E Kastritis","year":"2010","unstructured":"Kastritis E, Kyrtsonis MC, Hadjiharissi E, Symeonidis A, Michalis E, Repoussis P, et al. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom\u2019s macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leuk Res. 2010;34:1340\u20133.","journal-title":"Leuk Res"},{"key":"2297_CR13","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","volume":"113","author":"P Morel","year":"2009","unstructured":"Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113:4163\u201370.","journal-title":"Blood"},{"key":"2297_CR14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1586\/ehm.11.82","volume":"5","author":"P Morel","year":"2012","unstructured":"Morel P, Merlini G. Risk stratification in Waldenstr\u00f6m macroglobulinemia. Expert Rev Hematol. 2012;5:187\u201399.","journal-title":"Expert Rev Hematol."},{"key":"2297_CR15","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1182\/blood-2005-02-0833","volume":"107","author":"SP Treon","year":"2006","unstructured":"Treon SP, Gertz MA, Dimopoulos M, Anagnostopoulos A, Blade J, Branagan AR, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom\u2019s macroglobulinemia. Blood. 2006;107:3442\u20136.","journal-title":"Blood"},{"key":"2297_CR16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JCO.2008.17.7865","volume":"27","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, Leblond V, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom\u2019s Macroglobulinemia. J Clin Oncol. 2009;27:120\u20136.","journal-title":"J Clin Oncol"},{"key":"2297_CR17","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.2009.24.4905","volume":"28","author":"C Kyriakou","year":"2010","unstructured":"Kyriakou C, Canals C, Sibon D, Cahn JY, Kazmi M, Arcese W, et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28:2227\u201332.","journal-title":"J Clin Oncol"},{"key":"2297_CR18","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2006.07.8659","volume":"25","author":"CI Chen","year":"2007","unstructured":"Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom\u2019s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1570\u20135.","journal-title":"J Clin Oncol"},{"key":"2297_CR19","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","volume":"27","author":"SP Treon","year":"2009","unstructured":"Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, et al. Primary therapy of Waldenstr\u00f6m macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27:3830\u20135.","journal-title":"J Clin Oncol"},{"key":"2297_CR20","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2009.25.3237","volume":"28","author":"IM Ghobrial","year":"2010","unstructured":"Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010;28:1422\u20138.","journal-title":"J Clin Oncol"},{"key":"2297_CR21","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ajh.21788","volume":"85","author":"IM Ghobrial","year":"2010","unstructured":"Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstr\u00f6m Macroglobulinemia. Am J Hematol. 2010;85:670\u20134.","journal-title":"Am J Hematol"},{"key":"2297_CR22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s12185-015-1775-3","volume":"102","author":"M Izumi","year":"2015","unstructured":"Izumi M, Tsunemine H, Suzuki Y, Tomita A, Kusumoto T, Kodaka T, et al. Successful treatment of refractory cold hemagglutinemia in MYD88 L265P mutation-negative Waldenstr\u00f6m\u2019s macroglobulinemia with bortezomib. Int J Hematol. 2015;102:238\u201343.","journal-title":"Int J Hematol"},{"key":"2297_CR23","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203\u201310.","journal-title":"Lancet"},{"key":"2297_CR24","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1200\/JCO.2001.19.16.3596","volume":"19","author":"MA Dimopoulos","year":"2001","unstructured":"Dimopoulos MA, Zomas A, Viniou NA, Grigoraki V, Galani E, Matsouka C, et al. Treatment of Waldenstrom\u2019s macroglobulinemia with thalidomide. J Clin Oncol. 2001;19:3596\u2013601.","journal-title":"J Clin Oncol"},{"key":"2297_CR25","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1182\/blood-2008-04-150854","volume":"112","author":"SP Treon","year":"2008","unstructured":"Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood. 2008;112:4452\u20137.","journal-title":"Blood"},{"key":"2297_CR26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1158\/1078-0432.CCR-08-0862","volume":"15","author":"SP Treon","year":"2009","unstructured":"Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L, et al. Lenalidomide and rituximab in Waldenstrom\u2019s macroglobulinemia. Clin Cancer Res. 2009;15:355\u201360.","journal-title":"Clin Cancer Res"},{"key":"2297_CR27","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2015;372:1430\u201340.","journal-title":"N Engl J Med"},{"key":"2297_CR28","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/annonc\/mdj111","volume":"17","author":"SP Treon","year":"2006","unstructured":"Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C, et al. Characterization of familial Waldenstrom\u2019s macroglobulinemia. Ann Oncol. 2006;17:488\u201394.","journal-title":"Ann Oncol"},{"key":"2297_CR29","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2008-06-162768","volume":"112","author":"SY Kristinsson","year":"2008","unstructured":"Kristinsson SY, Bj\u00f6rkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma\/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood. 2008;112:3052\u20136.","journal-title":"Blood"},{"key":"2297_CR30","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1182\/blood-2009-10-247973","volume":"115","author":"RH Royer","year":"2010","unstructured":"Royer RH, Koshiol J, Giambarresi TR, Vasquez LG, Pfeiffer RM, McMaster ML. Differential characteristics of Waldenstr\u00f6m macroglobulinemia according to patterns of familial aggregation. Blood. 2010;115:4464\u201371.","journal-title":"Blood"},{"key":"2297_CR31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001. Blood. 2006;107:265\u201376.","journal-title":"Blood"},{"key":"2297_CR32","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ijc.28343","volume":"134","author":"M Iwanaga","year":"2014","unstructured":"Iwanaga M, Chiang CJ, Soda M, Lai MS, Yang YW, Miyazaki Y, et al. Incidence of lymphoplasmacytic lymphoma\/Waldenstr\u00f6m\u2019s macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996\u20132003. Int J Cancer. 2014;134:174\u201380.","journal-title":"Int J Cancer"},{"key":"2297_CR33","first-page":"253243","volume":"2014","author":"HS Lee","year":"2014","unstructured":"Lee HS, Kim K, Yoon DH, Kim JS, Bang SM, Lee JO, et al. Clinical factors associated with response or survival after chemotherapy in patients with Waldenstr\u00f6m macroglobulinemia in Korea. Biomed Res Int. 2014;2014:253243.","journal-title":"Biomed Res Int"},{"key":"2297_CR34","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.3760\/cma.j.issn.0366-6999.20140120","volume":"127","author":"S Yi","year":"2014","unstructured":"Yi S, Cui R, Li Z, An G, Qi J, Zou D, et al. Distinct characteristics and new prognostic scoring system for Chinese patients with Waldenstr\u00f6m macroglobulinemia. Chin Med J. 2014;127:2327\u201331.","journal-title":"Chin Med J"},{"key":"2297_CR35","unstructured":"Swerdlow SH, International Agency for Research on Cancer, World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008."},{"key":"2297_CR36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.12102","volume":"160","author":"RG Owen","year":"2013","unstructured":"Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, et al. Response assessment in Waldenstr\u00f6m macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013;160:171\u20136.","journal-title":"Br J Haematol"},{"key":"2297_CR37","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2297_CR38","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3816\/CLM.2009.n.016","volume":"9","author":"L Ioakimidis","year":"2009","unstructured":"Ioakimidis L, Patterson CJ, Hunter ZR, Soumerai JD, Manning RJ, Turnbull B, et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenstr\u00f6m\u2019s macroglobulinemia. Clin Lymphoma Myeloma. 2009;9:62\u20136.","journal-title":"Clin Lymphoma Myeloma."},{"key":"2297_CR39","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.3324\/haematol.2015.124149","volume":"100","author":"E Kastritis","year":"2015","unstructured":"Kastritis E, Kyrtsonis MC, Morel P, Gavriatopoulou M, Hatjiharissi E, Symeonidis AS, et al. Competing risk survival analysis in patients with symptomatic Waldenstr\u00f6m macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. Haematologica. 2015;100:e446\u20139.","journal-title":"Haematologica"},{"key":"2297_CR40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/leu.2008.261","volume":"23","author":"C Buske","year":"2009","unstructured":"Buske C, Hoster E, Dreyling M, Eimermacher H, Wandt H, Metzner B, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009;23:153\u201361.","journal-title":"Leukemia"},{"key":"2297_CR41","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2141.2011.08750.x","volume":"154","author":"SP Treon","year":"2011","unstructured":"Treon SP, Hanzis C, Manning RJ, Ioakimidis L, Patterson CJ, Hunter ZR, et al. Maintenance Rituximab is associated with improved clinical outcome in rituximab na\u00efve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol. 2011;154:357\u201362.","journal-title":"Br J Haematol"},{"key":"2297_CR42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ajh.23880","volume":"90","author":"R Banwait","year":"2015","unstructured":"Banwait R, Aljawai Y, Cappuccio J, McDiarmid S, Morgan EA, Leblebjian H, et al. Extramedullary Waldenstr\u00f6m macroglobulinemia. Am J Hematol. 2015;90:100\u20134.","journal-title":"Am J Hematol"},{"key":"2297_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14386","author":"JN Gustine","year":"2016","unstructured":"Gustine JN, Meid K, Hunter ZR, Xu L, Treon SP, Castillo JJ. MYD88 mutations can be used to identify malignant pleural effusions in Waldenstr\u00f6m macroglobulinaemia. Br J Haematol. 2016;. doi: 10.1111\/bjh.14386 .","journal-title":"Br J Haematol."},{"key":"2297_CR44","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","volume":"367","author":"SP Treon","year":"2012","unstructured":"Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2012;367:826\u201333.","journal-title":"N Engl J Med"},{"key":"2297_CR45","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","volume":"123","author":"SP Treon","year":"2014","unstructured":"Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014;123:2791\u20136.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-017-2297-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2297-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2297-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T08:59:00Z","timestamp":1719305940000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-017-2297-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,7]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["2297"],"URL":"https:\/\/doi.org\/10.1007\/s12185-017-2297-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2017,7,7]]}}}